A substantial $290.1M capital injection has been secured by Repligen Corporation, the Waltham, Massachusetts-based life sciences company. Repligen, a global firm focused on bioprocessing, provides innovative solutions essential for advancing biotherapeutic manufacturing. Its expertise spans filtration, chromatography systems, process analytics, fluid management, and proteins, supporting the development and production of a wide range of biologics, from cell and gene therapies to mRNA and monoclonal antibodies, across its 22 sites in the United States, Europe, and Asia-Pacific.


















